Evaluation of the effect of a natural product called Capsule 4 of edible fungi based on Ganoderma, Lentinula edodes, Trametes versicolor, Grifola frondosa on clinical and laboratory symptoms, respiratory and prognosis of patients with coronavirus and monkeypox referred to the Infectious Diseases Clinic of Imam Reza Hospital in 2022

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211020052819N1

Enrollment

100

Registered

2022-07-04

Start date

2022-06-25

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Severe Acute Respiratory Syndrome coronavirus

Interventions

Intervention 1: This study will be conducted as a three-blind randomized clinical trial for 5 days on 100 people infected with corona virus. For this purpose, 50 mild patients and 50 moderate hospital

Daily one capsule (each capsule containing 200 mg of the combination of 4 mushrooms). Supplements and placebo will be received after breakfast. For data analysis, SPSS version 22 software will be used

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Admission for COVID-19 patients, ranging in age from 18 to 70 years, No history for diabetes, hypertension, smoking, hypertension Positive PCR test for COVID-19

Exclusion criteria

Exclusion criteria: Patients with very large lung involvement and severe general condition and should be admitted to the intensive care unit. Reluctance to continue the plan Side effects that can cause the patient to stop the plan or leave the study after taking the supplement Creating any unwanted digestive problems including heartburn, nausea, nausea, vomiting, diarrhea, etc. Any allergies, whether skin, respiratory or other Creating any side effects that did not exist before taking the supplement

Design outcomes

Primary

Measure	Time frame
LDH. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;CBC diff. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;Na/ k/ Ca / SGOT / SGPT / Creatine / FBS/ Urea. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;ESR1. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;CRP. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;Weakness and nausea. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: check list.	—

Measure

Time frame

LDH. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;CBC diff. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;Na/ k/ Ca / SGOT / SGPT / Creatine / FBS/ Urea. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;ESR1. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;CRP. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: blood test.;Weakness and nausea. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: check list.

—

Secondary

Measure	Time frame
Determining the effect of supplementation on the amount of oxygen. Timepoint: 5 Days. Method of measurement: Pulse oximeter.;General condition of people and vitality after treatment. Timepoint: 5 Days. Method of measurement: En Examination and history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozhdeh Haddadi

Artesh University of Medical Sciences

mozhdeh_haddadi_777@yahoo.com+98 21 6642 7293

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026